Previous 10 | Next 10 |
EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now Testing Progr...
Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtua...
Oral Presentation of Preclinical Data on Inhibition of SETD2, a Histone Methyltransferase, in Multiple Myeloma to be Presented at the European Hematology Association (EHA) Congress Poster Presentation for Tazemetostat, a Methyltransferase Inhibitor, in Epithelioid Sarcoma at the A...
Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q1 2021 Earnings Call May 6, 2021 , 7:30 p.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q1 2021 Earnings Call Transcript
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...
The following slide deck was published by Epizyme, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
Epizyme (EPZM): Q1 GAAP EPS of -$0.69 misses by $0.12.Revenue of $7.63M (+465.2% Y/Y) beats by $0.76M.2021 Financial GuidanceBased on its current operating plans, Epizyme expects its current cash runway to extend into 2023. Additionally, the Company expects its non-GAAP adjusted operating exp...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...